Does DOSTARLIMAB Cause Malignant neoplasm progression? 111 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 111 reports of Malignant neoplasm progression have been filed in association with DOSTARLIMAB (Jemperli). This represents 12.4% of all adverse event reports for DOSTARLIMAB.
111
Reports of Malignant neoplasm progression with DOSTARLIMAB
12.4%
of all DOSTARLIMAB reports
38
Deaths
17
Hospitalizations
How Dangerous Is Malignant neoplasm progression From DOSTARLIMAB?
Of the 111 reports, 38 (34.2%) resulted in death, 17 (15.3%) required hospitalization, and 1 (0.9%) were considered life-threatening.
Is Malignant neoplasm progression Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for DOSTARLIMAB. However, 111 reports have been filed with the FAERS database.
What Other Side Effects Does DOSTARLIMAB Cause?
Thrombocytopenia (42)
Fatigue (38)
Anaemia (36)
Death (31)
Arthralgia (30)
Diarrhoea (29)
Rash (29)
Condition aggravated (27)
Dyspnoea (26)
Nausea (26)
What Other Drugs Cause Malignant neoplasm progression?
PEMBROLIZUMAB (10,111)
NIVOLUMAB (9,363)
ENZALUTAMIDE (4,696)
CARBOPLATIN (4,177)
EVEROLIMUS (3,789)
PACLITAXEL (3,484)
LETROZOLE (3,445)
IPILIMUMAB (3,296)
FULVESTRANT (3,221)
LENVATINIB (2,929)
Which DOSTARLIMAB Alternatives Have Lower Malignant neoplasm progression Risk?
DOSTARLIMAB vs DOSTARLIMAB-GXLY
DOSTARLIMAB vs DOTATATE GALLIUM GA-68
DOSTARLIMAB vs DOTHIEPIN
DOSTARLIMAB vs DOXAZOSIN
DOSTARLIMAB vs DOXAZOSIN\DOXAZOSIN